SEC Comment Letter 0000000000-24-003272 to DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc.
Date: March 26, 2024 · CIK: 0001401040 · Accession: 0000000000-24-003272
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278146
Letter
United States securities and exchange commission logo March 26, 2024 Rick Pauls President and Chief Executive Officer DiaMedica Therapeutics Inc. 301 Carlson Parkway, Suite 210 Minneapolis, MN 55305 Re:DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed March 21, 2024 File No. 333-278146 Dear Rick Pauls: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Amy E. Culbert, Esq.
Show Raw Text
United States securities and exchange commission logo
March 26, 2024
Rick Pauls
President and Chief Executive Officer
DiaMedica Therapeutics Inc.
301 Carlson Parkway, Suite 210
Minneapolis, MN 55305
Re:DiaMedica Therapeutics Inc.
Registration Statement on Form S-3
Filed March 21, 2024
File No. 333-278146
Dear Rick Pauls:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Amy E. Culbert, Esq.